Business Context and Reporting Period
This Form 8-K is filed by Lion Biotechnologies, Inc. (not IOVANCE BIOTHERAPEUTICS, INC.) for the reporting period ending December 5, 2014. The filing discloses executive compensation decisions, including stock option grants and year-end cash bonuses approved by the Board of Directors and Compensation Committee.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
- Stock Option Exercise Price: $6.25 per share (closing price on December 5, 2014).
- Option Term: 10 years.
- CEO Base Salary (2014): $350,000.
Material Changes and Compensation Details
The filing details specific compensatory arrangements for named executive officers effective December 5, 2014.
Stock Option Grants
| Officer | Title | Shares Granted |
|---|---|---|
| Laszlo Radvanyi, Ph.D. | Chief Scientific Officer | 32,407 |
| James Bender, Ph.D. | Vice President--Manufacturing | 46,666 |
| Michael Handelman | Chief Financial Officer | 40,000 |
Vesting Schedule: 1/3 vests on December 5, 2015; the remaining 2/3 vests over eight equal quarterly increments thereafter.
Cash Bonus Payments
| Officer | Title | Bonus Amount |
|---|---|---|
| Manish Singh, Ph.D. | Chief Executive Officer | $84,000 |
| Elma Hawkins, Ph.D. | President and Chief Operating Officer | $59,583 |
| Laszlo Radvanyi, Ph.D. | Chief Scientific Officer | $36,458 |
| James Bender, Ph.D. | Vice President--Manufacturing | $52,000 |
| Michael Handelman | Chief Financial Officer | $45,000 |
Dr. Singh's bonus represents approximately 24% of his 2014 base salary, below the maximum 30% eligible under his employment agreement.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is limited to the disclosure of Item 5.02 (Compensatory Arrangements).
Investor Verification Checklist
- Verify the correct registrant name is Lion Biotechnologies, Inc., as the metadata reference to "IOVANCE BIOTHERAPEUTICS, INC." appears to be an error in the request context.
- Confirm the total dilution impact of the 119,073 new stock options granted.
- Review the company's cash position to ensure it can support the aggregate cash bonus payout of approximately $277,041.
- Check subsequent filings for the actual vesting dates and any changes to the executive team.